We are live on ! Find out more
KYMR icon

Kymera Therapeutics
KYMR

126 hedge funds and large institutions have $1.93B invested in Kymera Therapeutics in 2022 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 60 increasing their positions, 32 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

312% more call options, than puts

Call options by funds: $10.6M | Put options by funds: $2.56M

88% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 32

3.77% more ownership

Funds ownership: 84.6% → 88.38% (+3.8%)

2% less funds holding

Funds holding: 128 → 126 (-2)

11% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 19

30% less capital invested

Capital invested by funds: $2.76B → $1.93B (-$825M)

33% less funds holding in top 10

Funds holding in top 10: 6 → 4 (-2)

Holders
126
Holders Change
-2
Holders Change %
-1.56%
% of All Funds
1.99%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.06%
New
17
Increased
60
Reduced
32
Closed
19
Calls
$10.6M
Puts
$2.56M
Net Calls
+$8M
Net Calls Change
-$535K

Top Buyers

1
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$27.3M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$25.1M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$22.4M
4
State Street
State Street
Massachusetts
+$19.1M
5
BI
BVF Inc
California
+$17.1M

Top Sellers

1
APM
Avidity Partners Management
Texas
-$42.5M
2
DCM
Driehaus Capital Management
Illinois
-$18.6M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$17.9M
4
LGM
Logos Global Management
California
-$12.7M
5
Jennison Associates
Jennison Associates
New York
-$11.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
AVLSA
1
Atlas Venture Life Science Advisors
Massachusetts
$291M – – –
T. Rowe Price Associates
2
T. Rowe Price Associates
Maryland
$165M +$14.6M +344,677 +10%
BI
3
BVF Inc
California
$152M +$17.1M +406,000 +13%
BlackRock
4
BlackRock
New York
$145M +$910K +21,544 +0.6%
Wellington Management Group
5
Wellington Management Group
Massachusetts
$137M +$22.4M +530,935 +20%
Vanguard Group
6
Vanguard Group
Pennsylvania
$120M -$5.04M -119,449 -4%
RG
7
Redmile Group
California
$111M +$1.15M +27,300 +1%
BBA
8
Baker Bros. Advisors
New York
$101M – – –
State Street
9
State Street
Massachusetts
$88.6M +$19.1M +452,799 +28%
Fidelity Investments
10
Fidelity Investments
Massachusetts
$81.4M -$17.9M -423,638 -18%
AG
11
Artal Group
Luxembourg
$42.3M – – –
ACA
12
Avoro Capital Advisors
New York
$34.6M +$11.3M +266,500 +48%
RSCM
13
Rock Springs Capital Management
Maryland
$32M +$583K +13,810 +2%
Bank of New York Mellon
14
Bank of New York Mellon
New York
$29M +$6.57M +155,476 +29%
Point72 Asset Management
15
Point72 Asset Management
Connecticut
$27.6M +$25.1M +594,600 +1,022%
PAMS
16
Pictet Asset Management (Switzerland)
Switzerland
$27.3M +$27.3M +646,075 New
Geode Capital Management
17
Geode Capital Management
Massachusetts
$26.4M +$157K +3,728 +0.6%
DMC
18
Deer Management Company
New York
$26.1M – – –
AIIC
19
AJU IB Investment Company
South Korea
$19.3M – – –
UBS AM
20
UBS AM
Illinois
$18.2M +$6.93M +164,192 +62%
CS
21
Candriam SCA
Luxembourg
$17.6M +$502K +11,894 +3%
SFM
22
Sphera Funds Management
Israel
$15.6M +$2.09M +49,394 +16%
Northern Trust
23
Northern Trust
Illinois
$13.5M -$804K -19,030 -6%
Charles Schwab
24
Charles Schwab
California
$10.8M +$285K +6,743 +3%
Goldman Sachs
25
Goldman Sachs
New York
$10.3M -$1.01M -23,864 -9%
1
2 3 4 5

KYMR Hedge Fund Activity: Q1 2022 in Review

126 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Kymera Therapeutics (KYMR) for Q1 2022, worth a combined $1.93B — down 30% from $2.76B a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of KYMR and 17 opened new positions — a net loss of 2 holders — while 32 trimmed existing stakes and 60 added.

The largest buyer was Pictet Asset Management (Switzerland), opening a new position worth an estimated $27.3M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $42.5M sold.

  • 126 institutional investors held Kymera Therapeutics (KYMR) as of Q1 2022, down from 128 in Q4 2021.
  • Funds reported $1.93B of Kymera Therapeutics stock for Q1 2022, down 30% quarter-over-quarter.
  • 17 funds opened new Kymera Therapeutics positions in Q1 2022 and 19 closed out, a net change of -2 holders.
  • The largest Kymera Therapeutics buyer in Q1 2022 was Pictet Asset Management (Switzerland), an estimated $27.3M added.
  • The largest Kymera Therapeutics seller in Q1 2022 was Avidity Partners Management, an estimated $42.5M sold.

Based on aggregated 13F filings for Q1 2022.